Orforglipron

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Orforglipron?

Orforglipron is an oral GLP-1 receptor agonist that belongs to a new class of non-peptide small molecule compounds designed to activate the glucagon-like peptide-1 (GLP-1) receptor. Originally discovered by Chugai Pharmaceutical and subsequently licensed to Eli Lilly, it was developed under the investigational name LY3502970 before receiving the international nonproprietary name orforglipron.

The compound represents a departure from traditional peptide-based GLP-1 receptor agonists. Peptide agonists like semaglutide, tirzepatide, liraglutide, exenatide, and dulaglutide are modified versions of native GLP-1 or exendin-4 peptides and typically require subcutaneous injection. Orforglipron, by contrast, is a chemically synthesised small molecule that binds the same receptor but can be absorbed orally and is resistant to enzymatic degradation in the gastrointestinal tract — a challenge that has historically limited oral peptide formulations.

Research interest in orforglipron centres on its potential to achieve metabolic effects comparable to injectable GLP-1 receptor agonists while offering the convenience of oral administration without fasting requirements. Its clinical development programme has generated substantial data from Phase 1 through Phase 3 trials in both obesity and type 2 diabetes populations.

Compound Profile

Mechanism of Action

The orforglipron mechanism of action involves selective, high-affinity binding to the human GLP-1 receptor with an inhibition constant (Kᵢ) of approximately 1 nM. Unlike peptide GLP-1 agonists, which are full agonists at the receptor, orforglipron functions as a partial agonist — a pharmacological distinction that has important implications for its signalling profile.

Competition binding experiments using radiolabelled GLP-1 and radiolabelled orforglipron have demonstrated that the compound occupies the same orthosteric binding site on the GLP-1 receptor but engages different receptor conformations compared to endogenous GLP-1 (PMID: 39693407). This results in what researchers term “biased agonism”: orforglipron preferentially activates the cyclic adenosine monophosphate (cAMP) signalling pathway while showing negligible recruitment of β-arrestin.

This signalling bias is significant because β-arrestin recruitment typically leads to receptor internalisation and desensitisation. By minimising β-arrestin engagement, orforglipron may maintain sustained receptor activation at the cell surface. The downstream effects of GLP-1 receptor activation by orforglipron include:

• Enhanced glucose-dependent insulin secretion from pancreatic β-cells
• Suppression of glucagon release from pancreatic α-cells during hyperglycaemia
• Delayed gastric emptying, contributing to reduced postprandial glucose excursions
• Central appetite regulation via hypothalamic GLP-1 receptor activation, reducing food intake

In preclinical models using mice engineered to express the human GLP-1 receptor, orforglipron demonstrated dose-dependent improvements in glucose tolerance that correlated with predicted receptor occupancy levels (PMID: 39693407). These findings confirm that despite its non-peptide structure, orforglipron engages the GLP-1 receptor in a pharmacologically productive manner consistent with therapeutic benefit.

Weight Loss Research

Orforglipron weight loss research has progressed from early-phase dose-finding studies to large-scale Phase 3 trials, generating a robust evidence base for its effects on body weight reduction.

Phase 2 Obesity Trial (PMID: 37351564)

In a pivotal Phase 2 randomised, double-blind trial, 272 adults with obesity (mean baseline BMI 37.9 kg/m²) without diabetes received once-daily orforglipron at doses of 12, 24, 36, or 45 mg, or placebo for 36 weeks. The primary endpoint — percentage change from baseline in body weight at week 26 — showed mean reductions ranging from −8.6% to −12.6% across orforglipron groups versus −2.0% with placebo. By week 36, weight loss reached −9.4% to −14.7% with orforglipron compared to −2.3% with placebo. Notably, 46–75% of participants receiving orforglipron achieved ≥10% weight loss at week 36, compared with 9% of those on placebo.

Phase 3 ATTAIN-1 Trial (PMID: 40960239)

The Phase 3 ATTAIN-1 trial enrolled 3,127 adults with obesity and without diabetes, randomised to orforglipron at 6 mg, 12 mg, or 36 mg, or placebo for 72 weeks. The mean change in body weight from baseline to week 72 was −7.5%, −8.4%, and −11.2% with the three orforglipron doses respectively, versus −2.1% with placebo. Among participants receiving the 36 mg dose, 54.6% achieved ≥10% weight loss, 36.0% achieved ≥15%, and 18.4% achieved ≥20%.

Meta-Analytic Evidence (PMID: 38414573)

A systematic review and meta-analysis pooling data from three randomised controlled trials involving 774 participants confirmed that orforglipron at 12–45 mg daily produced significantly greater percentage weight reductions than placebo. The odds of achieving >15% body weight loss were significantly higher across the 24–45 mg doses, with odds ratios ranging from 17 to 23 versus placebo.

These weight loss findings position orforglipron as a potentially impactful oral GLP-1 compound, though the magnitude of weight reduction in Phase 3 trials was somewhat more modest than that observed with injectable agents such as semaglutide 2.4 mg weekly.

Metabolic Effects

Beyond weight reduction, orforglipron research has demonstrated broad effects on metabolic parameters, particularly in populations with type 2 diabetes and insulin resistance.

Glycaemic Control in Type 2 Diabetes

In the Phase 2 type 2 diabetes trial (PMID: 37369232), 383 participants with T2D (mean baseline HbA1c 8.1%) received orforglipron at various doses, placebo, or dulaglutide 1.5 mg weekly for 26 weeks. The mean change in HbA1c with orforglipron reached up to −2.10% (placebo-adjusted −1.67%), compared with −0.43% for placebo and −1.10% for dulaglutide. HbA1c reduction with orforglipron was statistically superior to both placebo and the active comparator across the higher dose groups.

Phase 3 ACHIEVE-1 Trial (PMID: 40544435)

The Phase 3 ACHIEVE-1 trial randomised 559 participants with early type 2 diabetes (treated with diet and exercise only, mean baseline HbA1c 8.0%) to orforglipron 3 mg, 12 mg, 36 mg, or placebo for 40 weeks. The estimated mean changes from baseline in HbA1c were −1.24, −1.47, and −1.48 percentage points for the three orforglipron doses versus −0.41 with placebo (P<0.001 for all comparisons). Mean HbA1c levels at week 40 reached 6.5–6.7% in the orforglipron groups. The percent change in body weight was −4.5% with the 36 mg dose. Improvements in Cardiometabolic Markers

Across clinical trials, orforglipron treatment was associated with improvements in several cardiometabolic markers beyond glucose control. The Phase 3 ATTAIN-1 trial reported significant improvements in waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels compared with placebo (PMID: 40960239). These effects are consistent with the metabolic benefits observed with injectable GLP-1 receptor agonists and suggest broader cardiometabolic relevance beyond glycaemic control alone.

Cardiovascular Research

Cardiovascular outcomes data for orforglipron specifically are still emerging. No dedicated cardiovascular outcomes trial (CVOT) for orforglipron has been completed to date, which distinguishes it from established peptide GLP-1 receptor agonists that have extensive cardiovascular evidence.

However, several observations from the existing trial programme are relevant to cardiovascular research:

• Reductions in systolic blood pressure of approximately 2–5 mmHg have been observed across orforglipron trials, consistent with the class effect seen with injectable GLP-1 receptor agonists
• Significant reductions in triglycerides and non-HDL cholesterol were demonstrated in the Phase 3 ATTAIN-1 trial
• Improvements in waist circumference and overall adiposity may contribute to long-term cardiovascular risk reduction

The cardiovascular safety and benefit profile of the broader GLP-1 receptor agonist class has been established through large CVOTs with semaglutide (SELECT trial) and liraglutide (LEADER trial), among others. Whether orforglipron as a non-peptide GLP-1 agonist with partial agonist pharmacology will replicate these cardiovascular benefits is an active area of investigation. Dedicated cardiovascular outcomes trials are expected as part of the broader orforglipron clinical programme.

Orforglipron Side Effects

The orforglipron side effects profile has been characterised across Phase 1 through Phase 3 clinical trials. The safety data are consistent with the known class effects of GLP-1 receptor agonists, with gastrointestinal events predominating.

Gastrointestinal Adverse Events

Across all trials, the most commonly reported adverse events were gastrointestinal in nature. In the Phase 2 obesity trial (PMID: 37351564), these included nausea, vomiting, diarrhoea, and constipation. These events were generally mild to moderate in severity and occurred most frequently during the dose escalation period, with rates diminishing at stable maintenance doses. Discontinuation due to adverse events ranged from 10–17% across dose cohorts in the Phase 2 obesity trial.

In the Phase 3 ATTAIN-1 trial, adverse events led to treatment discontinuation in a dose-dependent pattern, though the overall safety profile was described as consistent with that of GLP-1 receptor agonists (PMID: 40960239).

Meta-Analytic Safety Data (PMID: 37852529)

A systematic review and meta-analysis evaluating the safety of oral small-molecule GLP-1 receptor agonists (including orforglipron and danuglipron) across seven randomised controlled trials involving 1,037 patients found significantly higher odds of gastrointestinal adverse events compared to controls (OR 2.57; 95% CI 1.49–4.42). However, the odds of severe hypoglycaemia and serious adverse events were not significantly different from controls (OR 0.34 and 0.95, respectively), suggesting that orforglipron does not introduce novel severe safety signals beyond the expected GLP-1 class effects.

Other Reported Events

Additional adverse events reported in clinical trials include decreased appetite (an expected pharmacological effect), headache, and dizziness. No pancreatitis signals or thyroid-related safety concerns have emerged from the clinical programme to date, though long-term surveillance data are limited and ongoing trials continue to monitor for these class-associated risks.

Pharmacokinetics

The pharmacokinetic profile of orforglipron has been characterised in dedicated Phase 1 studies and pharmacokinetic sub-studies within later-phase trials.

Absorption and Half-Life

Phase 1 data (PMID: 37344954) demonstrate that orforglipron exhibits approximately dose-proportional pharmacokinetics. After a single dose (0.3–6 mg range), the mean elimination half-life ranged from 24.6 to 35.3 hours. With repeated daily dosing over 28 days (2–24 mg range), the mean half-life extended to 48.1–67.5 hours, consistent with accumulation to steady state. This long half-life supports once-daily oral administration.

Food Effect

A dedicated food effect study (PMID: 38402332) assessed orforglipron pharmacokinetics under fed and fasted conditions. While AUC and Cmax were modestly lower in the fed state (by approximately 18–24%), these differences were not considered clinically meaningful. Importantly, the elimination half-life and time to maximum concentration were comparable between fed and fasted conditions. This finding supports administration without prandial restrictions — a practical advantage over oral semaglutide, which requires fasting.

Metabolism and Elimination

Orforglipron is primarily metabolised by hepatic pathways. Its small molecule structure confers resistance to the peptidase degradation that limits oral bioavailability of peptide-based GLP-1 agonists, enabling reliable gastrointestinal absorption without the need for absorption enhancers or protective formulations.

Dose-Response Relationship

Across the Phase 1b study in type 2 diabetes participants (PMID: 37264711), orforglipron demonstrated clear dose-response relationships for both pharmacokinetic exposure and pharmacodynamic endpoints including fasting glucose reduction and body weight changes. Substantial reductions in body weight of up to 5.4 kg were observed after just 4 weeks of treatment in the Phase 1a study, compared to 2.4 kg with placebo.

FAQ

Is orforglipron a peptide?

No. Orforglipron is a non-peptide small molecule GLP-1 receptor agonist, not a peptide. However, it targets the same GLP-1 receptor as peptide-based agonists like semaglutide and liraglutide. It is included in peptide research references because it represents the evolution of GLP-1 receptor pharmacology from peptide to small molecule compounds, and its development was built on decades of peptide GLP-1 research.

How does orforglipron differ from oral semaglutide?

While both are oral GLP-1 receptor agonists, they differ fundamentally in molecular structure. Oral semaglutide is a peptide formulated with an absorption enhancer (SNAC) and requires a 30-minute fasting period before the first food or drink of the day. Orforglipron is a small molecule that does not require fasting or water restrictions, as food has only modest effects on its pharmacokinetics that are not considered clinically meaningful (PMID: 38402332).

What is the orforglipron mechanism of action?

Orforglipron acts as a partial agonist at the GLP-1 receptor with biased signalling properties. It preferentially activates the cAMP pathway while showing negligible β-arrestin recruitment (PMID: 39693407). This leads to enhanced insulin secretion, reduced glucagon release, delayed gastric emptying, and central appetite suppression — effects comparable to those of injectable GLP-1 receptor agonists.

What weight loss has been observed in orforglipron research?

In Phase 2 research, orforglipron produced mean body weight reductions of −9.4% to −14.7% over 36 weeks in adults with obesity (PMID: 37351564). In the Phase 3 ATTAIN-1 trial over 72 weeks, the 36 mg dose produced −11.2% mean weight loss, with 54.6% of participants achieving ≥10% weight loss (PMID: 40960239). These figures are meaningful but generally more modest than those reported with injectable semaglutide or tirzepatide.

What are the most common orforglipron side effects?

Gastrointestinal adverse events are the most frequently reported side effects in clinical trials, including nausea, vomiting, diarrhoea, and constipation. These events are generally mild to moderate, occur most commonly during dose escalation, and tend to diminish at stable maintenance doses. Meta-analytic data confirm that serious adverse events and severe hypoglycaemia are not significantly increased compared to controls (PMID: 37852529).

Who developed orforglipron?

Orforglipron was originally discovered by Chugai Pharmaceutical Co. in Japan and was subsequently licensed to Eli Lilly and Company in 2018 for further development. Eli Lilly conducted the full clinical development programme under the investigational name LY3502970, progressing through Phase 1, Phase 2, and Phase 3 trials in both obesity and type 2 diabetes.

What is the half-life of orforglipron?

Orforglipron has a long elimination half-life that supports once-daily oral administration. In Phase 1 studies, the single-dose half-life ranged from 24.6 to 35.3 hours, while with repeated daily dosing over 28 days the mean half-life extended to 48.1–67.5 hours (PMID: 37344954). This accumulation to steady state is expected and contributes to consistent daily plasma levels.

How does orforglipron compare with tirzepatide for weight loss?

Direct head-to-head trials between orforglipron and tirzepatide have not been conducted. In cross-trial comparisons, orforglipron 36 mg produced −11.2% mean weight loss at 72 weeks (ATTAIN-1), while tirzepatide at its highest doses has produced mean weight reductions exceeding 20% in the SURMOUNT programme. Tirzepatide is a dual GIP/GLP-1 receptor agonist, which may account for the greater weight loss magnitude. Orforglipron’s oral formulation without injection requirements represents a different value proposition in the research landscape.

Can orforglipron be taken with food?

Pharmacokinetic research indicates that food consumption modestly reduces orforglipron absorption (AUC reduced by approximately 18–24%) but that these differences are not considered clinically meaningful (PMID: 38402332). Unlike oral semaglutide, orforglipron does not require fasting before or after administration, which simplifies its use in research and clinical settings.

What is the current regulatory status of orforglipron?

Orforglipron has received FDA approval under the brand name Foundayo. Phase 3 clinical trial results have been published in the New England Journal of Medicine for both obesity (ATTAIN-1, PMID: 40960239) and type 2 diabetes (ACHIEVE-1, PMID: 40544435), with additional trials in the broader clinical programme ongoing.

References

1. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. PMID: 37351564
2. Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472-483. PMID: 37369232
3. Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634-2641. PMID: 37344954
4. Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25(9). PMID: 37264711
5. Sloop KW, Cox AL, Wainscott DB, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024;16(778):eadp5765. PMID: 39693407
6. Dutta D, et al. Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: a systematic review and meta-analysis. Obes Sci Pract. 2024;10(2):e743. PMID: 38414573
7. Karakasis P, et al. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2023;149:155710. PMID: 37852529
8. Ma X, et al. Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970). Diabetes Ther. 2024;15(4). PMID: 38402332
9. Wharton S, Stefanski A, Alfaris NF, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. PMID: 40960239
10. Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. PMID: 40544435